Sue Griffin
Vice President - Translational Haematology & Tumour Omics, Oncology & Translational Research GSK
Sue Griffin is Vice President of Translational Haematology and Tumour ‘Omics at GSK where she provides strategic leadership for haematology translational research, focusing on biomarker-driven research. Previously, she served as Executive Director, Immuno-Oncology Research Unit at GSK, where she led a global team supporting target identification/validation, preclinical portfolio progression, translational biology and clinical asset support for immuno-oncology and haematology. Earlier in her career, Sue was a Scientific Leader in Antibody Technologies, Biopharm Discovery, GSK, and a Senior Scientist at Horizon Discovery. She holds a PhD in haematology from the University of Cambridge and an MBiol in Molecular and Cellular Biology from the University of Bath.
Seminars
- Highlighting the importance of in-depth translational characterisation of late-stage ADC assets to understand clinical success
- Explaining how belantamab Mafodotin mechanism of action enables durable patient responses in the clinic
- Laying out lessons learnt that can influence how subsequent and future ADCs are designed
